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Abstract
Background & Aims—Levator ani syndrome (LAS) might be treated using biofeedback to teach
pelvic floor relaxation, electrogalvanic stimulation (EGS), or massage of levator muscles. We
performed a prospective, randomized controlled trial to compare the effectiveness of these techniques
and assess physiological mechanisms for treatment.
Methods—Inclusion criteria were Rome II symptoms plus weekly pain. Patients were categorized
as “highly likely” to have LAS if they reported tenderness with traction on the levator muscles, or
as “possible” LAS if they did not. All 157 patients received 9 sessions including psychological
counseling plus biofeedback, EGS, or massage. Outcomes were reassessed at 1, 3, 6, and 12 months.
Results—Among patients with “highly likely” LAS, adequate relief was reported by 87% for
biofeedback, 45% for EGS, and 22% for massage. Pain days per month decreased from 14.7 at
baseline to 3.3 after biofeedback, 8.9 after EGS, and 13.3 after massage. Pain intensity decreased
from 6.8 (0–10 scale) at baseline to 1.8 after biofeedback, 4.7 after EGS, and 6.0 after massage.
Improvements were maintained for 12 months. Patients with only a “possible” diagnosis of LAS did
not benefit from any treatment. Biofeedback and EGS improved LAS by increasing the ability to
relax pelvic floor muscles and evacuate a water-filled balloon, and by reducing the urge and pain
thresholds.
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Conclusions—Biofeedback is the most effective of these treatments, and EGS is somewhat
effective. Only patients with tenderness on rectal examination benefit. The pathophysiology of LAS
is similar to that of dyssynergic defecation.
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Introduction
Levator ani syndrome (LAS) is defined by chronic or recurring episodes of rectal pain or aching
in the absence of structural or systemic disease explanations for these symptoms1. The
diagnosis is said to be “highly likely” if the patient reports tenderness on palpation of the levator
ani muscles and only “possible” in the absence of tenderness. The Rome III criteria2 use the
term “chronic proctalgia” to refer to the same symptoms. This syndrome affects an estimated
6.6% of adults3. The pain may be severe and is associated with increased work absenteeism3.
There is no consensus on its pathophysiology, although chronic tension or “spasm” of the
striated pelvic floor muscles is the most common view2.
The three most frequently recommended treatments for LAS1, 2 are biofeedback to teach
relaxation of the pelvic floor muscles4-8, electrogalvanic stimulation (EGS)6, 9-11, and digital
massage of the levator muscles8. Uncontrolled trials support the efficacy of each of these, but
reported rates of improvement have been highly variable12, 13. The goals of this randomized
controlled trial were (1) to identify which of these treatments yields the greatest clinical benefit
and estimate the proportion of patients likely to respond, (2) determine whether clinical benefits
are sustained for at least 12 months, (3) determine which physiological measures change with
treatment, and (4) identify patient characteristics that predict who is most likely to benefit from
these treatments. An additional goal was to compare patients with a highly likely diagnosis to
those with a possible diagnosis of LAS.
A physiological assessment which included anorectal manometry and balloon defecation was
carried out at baseline and at 1 and 3 months follow-up in order to test the following hypotheses:
(1) Patients who achieve adequate relief of LAS will exhibit greater reductions in resting anal
canal pressure than patients who do not. (2) Adequate relief of LAS will be associated with
the ability to evacuate a 50-ml water-filled balloon.
Methods
Subjects
All patients referred to the Valeggio sul Mincio Section, Division of Gastroenterology of the
University of Verona at Verona and Valeggio sul Mincio-Department of Biomedical and
Surgical Sciences during a 6-year period (October 2000 to November 2006) with chronic or
recurrent rectal pain or aching suggestive of LAS were screened (Figure 1). Inclusion criteria
were chronic or recurrent rectal pain or aching for at least 12 weeks in the last year, with pain
or discomfort lasting at least 20 minutes1. For this study, subjects were further required to have
at least one episode of rectal pain per week during a 4-week run-in. Individuals aged 18-70
who fulfilled all of these symptom criteria and had none of the exclusion criteria (see below)
were classified as “highly likely” LAS if they reported tenderness with palpation of the levator
ani muscles and as “possible” LAS if they did not report tenderness. The examination for
tenderness involved pressing vigorously three times in random order on the posterior, left, and
right aspects of the pelvic floor, and was reported as positive only if the patient reported
tenderness on two out of three trials in the same location.
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Exclusion criteria based on Rome II included (1) fulfilling Rome II symptom criteria for
irritable bowel syndrome or functional constipation, (2) overt psychopathology or daily use of
anxiolytic or antidepressant medications, or (3) pelvic diseases that could produce similar
symptoms. The medical examination to exclude pelvic diseases consisted of digital rectal
examination by a gastroenterologist, colonoscopy, pelvic ultrasound, and surgical consultation
in all patients, plus referral to a gynecologist or urologist when indicated by clinical history or
findings. Patients with prior exposure to any of the three treatments were also excluded.
As shown in Figure 1, 227 patients meeting symptom criteria for LAS underwent medical
screening for other diseases leading to the exclusion of 33 patients. The remaining 194 patients
were given a full description of the study including all elements of informed consent and were
invited to participate; however, 10 refused leaving 184 to be screened by a 4-week run-in. At
the end of the run-in, an additional 27 patients were excluded (17 for keeping inadequate
records and 10 for having less than weekly episodes of rectal pain). The remaining 157 patients
were randomized to the three treatment arms. This study was conducted in accord with the
World Medical Association Declaration of Helsinki as amended in 1989
(www.fda.gov/oc/health/helsinki89.html) and CONSORT guidelines14. Ethics approval was
obtained from the Internal Review Board of the Department of Biomedical and Surgical
Sciences of the University of Verona.
Study design
This was a parallel group study with stratified randomization to insure equal ratios of “certain”
to “possible” LAS diagnoses in each treatment arm. All patients first underwent a 4-week run-
in period to confirm inclusion criteria. The run-in also constituted a baseline assessment for
comparison to post-treatment outcomes. Stratified randomization was accomplished by
preparing two sets of sealed envelopes containing group assignments ahead of time and
shuffling these; at the end of the run-in, eligible subjects were assigned to a treatment group
by opening the next envelope from the appropriate set depending on whether the subject had
a certain or a possible diagnosis of LAS. The principal investigator (GC) prepared the envelopes
containing randomization codes and shuffled these prior to study initiation. The next treatment
assignment was not predictable. Treatment involved 9 sessions for all treatment arms. All
patients were requested to complete follow-up assessments 1, 3, and 6 months after the end of
treatment, and all subjects who reported adequate relief at 6 months follow-up were telephoned
at 12 months to ask about adequate relief. The primary outcome was a report of adequate relief.
All outcome assessment was carried out by a nurse co-investigator who was blind to treatment
assignment. This study is registered in ClinicalTrials.gov as NCT00947180.
Treatment
Biofeedback
The biofeedback treatment was identical to that described for dyssynergic defecation15, 16.
This biofeedback protocol was selected because it was known to be effective for reducing
pelvic floor muscle tension in a different disorder, pelvic floor dyssynergia15, 16. However,
the investigators did not initially assume that the pathophysiology of dyssynergic defecation
would be identical to that of LAS. Biofeedback training involved 5 weekly training sessions.
Patients were first taught to strain more effectively by holding their breath, lowering their
diaphragm, and contracting abdominal wall muscles. Next they were taught to relax pelvic
floor muscles during straining using a surface intra-anal EMG probe connected to a portable
biofeedback instrument (Myotron-120, Enting Instruments & Systems, Dorst, The
Netherlands). The averaged EMG signal was displayed in microvolts. In the final phase of
training, patients practiced defecating a 50-ml air-filled balloon while the therapist gently
pulled on the plastic tube connected to the balloon. Five 30-minute biofeedback sessions were
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followed by 4 sessions of counseling to provide contact time with the therapist and counseling
that was equivalent to the other two study arms. Counseling involved discussions of the
circumstances of pain episodes in order to identify possible triggers for pain and teach strategies
to avoid or cope with these trigger situations.
Electrogalvanic stimulation
Nine 30-45 minutes treatment sessions with high-voltage EGS were delivered 3 times/week
using a commercially available self-retaining intra-anal probe (Sohn's Electrode, Electro-Med
Health Industries, Miami, Florida) connected to an electrogalvanic stimulator (Model 100-2,
Electro-Med Health Industries, Miami, Florida). Because no optimal treatment parameters for
LAS have been established, we used the stimulation protocol we previously described for
dyssynergic defecation17. Pulse frequency was 80 cycles per second. Voltage was gradually
increased from 0 to 150-350 volts, depending on the patient's tolerance. Counseling was
provided during these sessions using the same techniques described for the biofeedback arm.
Digital massage and sitz baths
Three times each week for a total of 9 clinic visits, the therapist massaged the patient's levator
muscles following a previously described protocol8. Digital pressure was applied as strongly
as the patient could tolerate, rotating the finger from side to side. The number of times this
maneuver was performed in each therapeutic session was 4-6 in the initial session, based on
the patient's tolerance, and was increased up to 20 times per session in subsequent sessions.
Patients were taught to perform digital massage on themselves and instructed to do this twice
a day at home after taking a warm sitz bath. Counseling was also provided following the
protocol described above. Sessions lasted 30-45 minutes. Because self-treatment by inserting
a finger into the rectum twice a day may be objectionable to some patients, they were questioned
about adherence at every follow-up visit. All patients reported massaging their pelvic floor
muscles twice a day during the first month, but by 3 months most were practicing massage
only once a day, and by 6 months most had discontinued digital massage.
Physiological assessment
Anorectal manometry and balloon expulsion tests were carried out prior to the run-in and at
the 1-month and 3-month follow-up points. The purposes of the baseline anorectal manometry
test were (1) to confirm that LAS is associated with elevated anal canal pressure and (2) to
identify predictors of response to therapy. The purpose of the baseline balloon defecation test
was to determine whether the same physiological mechanism is responsible for LAS and
dyssynergic defecation. The post-treatment anorectal manometry and balloon expulsion tests
served to evaluate the mechanisms responsible for clinical improvement.
Anorectal manometry technique
The manometry catheter (model R6B; Mui Scientific, Missisauga, Ontario, Canada) had a
disposable latex balloon on its tip that could be distended with air using a hand-held syringe,
and it had 4 perfusion ports spaced 1 cm apart beginning 2 cm below the balloon to measure
anal canal pressures. The inner diameter of each of the 4 perfusion catheters was 0.8 mm, and
they were perfused with degassed water at a rate of 0.5mL/min using a low compliance pump
(Arndorfer Medical Specialties, Greendale, WI). The outer diameter of the catheter was 4.5
mm. Pressures were recorded and displayed using a model GR800 polygraph (Aspen Medical,
Dingwall, Scotland). Previously described procedures18 were used to measure (1) anal canal
resting pressure (defined as the average of 4 pressure sensors in the region of highest pressure
during stationary pull-through), (2) response to straining to defecate (whether a paradoxical
increase in anal canal pressure, an incomplete relaxation, or a normal relaxation), (3) lowest
(threshold) volume of rectal distention required to elicit a rectoanal inhibitory reflex (RAIR),
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(4) urge threshold defined as the minimum volume of rectal distention required to elicit a
sensation of urgency to defecate, (5) pain tolerance defined as the maximum volume of rectal
distention that the patient was able (willing) to tolerate, and (6) compliance of the rectum
defined as the pressure in the distending balloon when 100 ml of air was inflated. (The last is
an inverse measure of compliance; higher balloon pressures at 100 ml distention reflect
decreased compliance.) Manometric tracings were scored manually by one investigator who
was blind to the patient's treatment group.
Balloon defecation test
A lubricated Foley catheter was inserted into the rectum and filled with 50 ml of water. The
patient was asked to expel this balloon within 5 minutes while sitting on a toilet in a private
bathroom, and the test was scored as successful or failed.
Outcome measures
The primary outcome was the patient's response at one month follow-up to the question,
“Compared to before you started treatment, have you experienced adequate pain relief (Yes or
No)”. The adequate relief question was repeated at 3 and 6 months follow-up for all patients,
and patients reporting adequate relief at 6 months were asked about adequate relief by telephone
at 12 months follow-up. All adequate relief questions were asked by a registered nurse who
was unaware of treatment assignment. Patients who did not return for follow-up or who did
not respond to the adequate relief question were treated as non-responders in the intent-to-treat
analysis at each assessment point.
Multiple secondary end points were used to support the primary outcome:
1. Subjective pain improvement was evaluated on an ordinal scale at 1, 3, and 6 months
follow-up by asking the patient, “Compared to before you started treatment, how
would you rate your pain?” Possible answers were: -2 = a lot worse, -1 = a little worse,
0 = same as before, +1 = a little better, +2 = fairly better, and +3 = a lot better or cured.
2. Number of days per month with rectal pain was inferred from a 30-day symptom log
kept during run-in and prior to scheduled follow-up appointments at 1, 3, and 6
months. The therapist was kept blind to diary responses.
3. Visual analog scale (VAS) ratings of pain (10 cm lines anchored with the words “pain
free” at the left end and “worst pain ever experienced” at the right end) were completed
weekly during the 30-day symptom diary. Patients were asked to rate the worst pain
experienced during the previous week. The average of the 4 weekly VAS ratings was
calculated for baseline and each follow-up point.
4. Self-reported stool frequency was assessed at baseline and at the 6-month follow-up
visit by asking the patient how many bowel movements they remembered having in
the previous week.
Statistical power and analysis plan
The primary efficacy analysis was a Chi square test of the proportion of subjects reporting
adequate relief one month after treatment ended. There were no missing data at one month.
For subsequent follow-up points, subjects with missing data on adequate relief were assumed
to be non-responders and analysis was by intent-to-treat. Sample size was based on feasibility,
i.e., the number of potential subjects available within a 6-year period. However, statistical
power was calculated to be approximately 77% to detect a 25% difference between groups in
the proportion reporting adequate relief at an unadjusted alpha of 0.025.
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After analyzing the pooled sample, we separated the patients into those with a highly likely
diagnosis of LAS vs. those with a possible diagnosis and repeated the efficacy analysis for
each of these subsets.
Three of the secondary outcome measures (number of pain days per month, average VAS pain
rating, and number of stools per week) were continuous, and the other secondary outcome
measure was an ordinal scale rating (subjective improvement in pain). These were analyzed
by analysis of variance (ANOVA), and missing values were replaced by the last observation
carried forward. These secondary outcomes were analyzed first in all patients with chronic
proctalgia and then separately for those with a highly likely and those with a possible diagnosis
of LAS. The physiological mediator variables were analyzed by ANOVA (for continuous
variables) or Chi square (for dichotomous variables) at each follow-up interval without
replacement of missing values. General linear modeling19 for repeated measures was used to
assess the impact of treatment on average stool frequency, and logistic regression was used to
evaluate patient characteristics that predict who will respond to biofeedback training with
adequate relief of pain. For all analyses, p<0.025 was considered significant.
Results
The groups were similar in age, sex, duration of illness, baseline stool frequency, and prior use
of medications to manage their chronic proctalgia (Table 1). Most had tried narcotics and
antispasmodic medications without significant benefit. Due to stratification, the proportion of
subjects with a highly likely diagnosis was similar in all three treatment groups (Figure 1).
There were no differences at baseline in the number of days per month with pain or the average
intensity of pain (Figures 2-3).
Comparison of treatments
Table 2 shows the intent to treat analysis for the primary outcome measure, adequate relief of
pain. Patients with a highly likely diagnosis and those with a possible diagnosis of LAS were
pooled. These data show that biofeedback treatment was superior to both EGS and massage at
all follow-up points, but EGS and massage were not significantly different from each other.
Figure 4 divides the patients into those with a highly likely diagnosis of LAS vs. those with a
possible diagnosis and shows the 95% confidence intervals for the responder rate at each time
point. Significant improvements in adequate relief occurred exclusively in patients with a
highly likely diagnosis of LAS. Moreover, among those with a highly likely diagnosis of LAS,
EGS was significantly better than massage at 1 and 3 months but not at 6 or 12 months follow-
up.
Analyses of the secondary outcome variables confirmed the results of the primary analysis:
For patients with a highly likely diagnosis of LAS, subjective ratings of improvement in pain
(Figure 5) increased significantly more with biofeedback than with EGS or massage, and the
EGS group reported significantly more improvement than the massage group at 1, 3, and 6
months follow-up. The number of days per month with pain (Figure 2) decreased significantly
more with biofeedback than with massage or EGS at all follow-up points, and EGS was
significantly better than massage at all follow-up points. The average VAS rating of pain
(Figure 3) likewise decreased significantly more with biofeedback than with EGS or massage,
and the EGS group improved significantly more than the massage group. Patients with a
possible diagnosis of LAS did not show significant treatment benefits on any of the secondary
outcomes.
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Physiological differences between patients with a highly likely diagnosis vs. those with a
possible diagnosis of LAS
The principal differences separating those who reported tenderness on palpation of the levator
muscles (highly likely diagnosis) from those who did not report tenderness were (1) failure to
decrease anal canal pressures when straining and (2) inability to evacuate a 50 ml water-filled
balloon: 14% of those with a highly likely diagnosis decreased anal canal pressures when
straining compared to 71% of those with only a possible diagnosis, and 13% with a highly
likely diagnosis were able to defecate a 50-ml water filled balloon compared to 71% of those
with only a possible diagnosis of LAS. On all other physiological variables measured, patients
with a highly likely diagnosis of LAS were not different from patients with a possible diagnosis
of LAS.
Mechanism of treatment
Table 3 shows changes in physiological measures from baseline to 1 month and 3 months
following treatment in each treatment group. In those with a highly likely diagnosis of LAS
(left side of Table 3), biofeedback training was associated with restoration of the ability to relax
anal canal pressures when straining (94% successful) and ability to defecate a water-filled
balloon (97% successful). Patients treated with EGS also showed significant improvements in
ability to relax pelvic floor muscles when straining and ability to pass a water-filled balloon,
but they were significantly less likely to be successful than patients treated with biofeedback
(Table 3, left side). Patients treated with massage did not significantly improve their ability to
relax anal canal pressures, but they did show significant improvements in their ability to
evacuate water-filled balloons.
In patients with only a possible diagnosis of LAS (right side of Table 3), biofeedback was
associated with significant increases in the proportion of patients who could relax anal canal
pressures when straining and the proportion who could evacuate a 50-ml water filled balloon.
However, among those with only a possible diagnosis of LAS, neither EGS nor massage was
associated with significant improvement in these parameters.
For patients with a highly likely diagnosis of LAS (left side of Table 3), treatment with
biofeedback was also associated with significant decreases in urge threshold and maximum
tolerable volume at both 1 and 3 month follow-up assessments, and increased compliance at
one month. EGS produced similar changes in urge threshold and maximum tolerable volume,
but massage did not. Massage was associated with a significant reduction in resting anal canal
pressure, which was not seen in the biofeedback and EGS treatment arms. For patients with
only a possible diagnosis of LAS (right side of Table 3), none of these physiological parameters
were significantly improved by biofeedback, EGS, or massage.
The data in Table 3 suggest that the mechanism for achieving adequate relief of rectal pain was
an improvement from being unable to relax anal canal pressures during straining to being able
to do so, and/or an improvement from being unable to evacuate a 50-ml water filled balloon
to an ability to do so. In a post hoc test of this hypothesis, we pooled all subjects regardless of
treatment group and level of diagnostic confidence and compared those who showed an
improvement in either of these parameters to those who showed no change (where no change
could mean either inability to relax pelvic floor muscles and/or defecate a balloon at baseline
which remained the same after treatment, or no change could mean that the patient was able
to relax pelvic floor muscles and/or defecate a balloon at baseline and could also do so after
treatment). This analysis showed that 94.2% of those who demonstrated improved pelvic floor
dysfunction reported adequate relief whereas only 13.6% of those whose pelvic floor function
was unchanged following treatment reported adequate relief (χ2=93.14, p<0.001).
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The pathophysiology of LAS revealed by these analyses appears identical to that seen in pelvic
floor dyssynergia type constipation1, 15. To explore this similarity, we compared stool
frequency at baseline to stool frequency recorded at six month follow-up using General Linear
Models for repeated measures19. Average stool frequency at baseline was within the normal
range at 6.5 stools per week because the exclusion criteria required that any patient who met
criteria for functional constipation be excluded. Nevertheless, 6 months following treatment
stool frequency had increased significantly to 7.6 stools per week in patients who reported
adequate relief while stool frequency remained unchanged at 6.6 stools per week in patients
who did not report adequate relief (F=137.03, p<0.001). Neither type of treatment nor level of
diagnostic confidence was significantly related to the magnitude of this increase in stool
frequency.
Patient characteristics recorded prior to treatment that predict response to biofeedback
Logistic regression was used to identify baseline variables that could predict adequate relief at
one-month follow-up for patients treated with biofeedback. Baseline observations could
account for 86.7% of the variance in outcome (Nagelkerke's R2, χ2=53.424, p<0.001), with the
best predictors being tenderness on physical examination (p=0.014) and a higher urge threshold
(p=0.045). Inability to pass a 50-ml water-filled balloon and failure to relax anal canal pressures
when straining were also highly correlated with response to treatment, but they dropped out of
the regression analysis due to their high correlation with another predictor variable, pain on
physical examination.
Adverse events
No adverse events were reported.
Discussion
This study compared the three most commonly recommended treatments for levator ani
syndrome in an adequately-powered, randomized controlled study and demonstrated that
biofeedback is significantly more effective than electrogalvanic stimulation or digital massage.
When all patients meeting criteria for inclusion were included in the intent-to-treat analysis,
59.6% of biofeedback-treated patients reported adequate relief one month after treatment
compared to 32.7% of EGS and 28.3% of massage treated patients. The reductions in rectal
pain following biofeedback training were sustained for at least one year. When the analysis
was restricted to patients with a highly likely diagnosis of LAS (i.e., those who report
tenderness on palpation of the levator muscles), the proportion who reported adequate relief
rose to 87.1% at one month follow-up in the biofeedback group.
The superiority of biofeedback was supported by all secondary outcomes: Biofeedback treated
patients showed greater reductions in VAS ratings of pain and number of days per month with
rectal pain, and they also reported greater improvement in pain on an ordinal scale at all time
points. Although EGS and massage appeared to be comparable to each other when evaluated
on the adequate relief measure, EGS was superior to massage on most secondary outcome
measures, suggesting a possible but weaker benefit for EGS compared to biofeedback.
Previous studies of the treatment of chronic rectal pain were mostly uncontrolled case series
or retrospective reports, and success rates for biofeedback6-8, EGS9-11, 13, 20, and massage21,
22 were all highly variable. A single prospective, quasi-randomized study12 compared EGS to
local injection of triamcinolone acetonide, but success rates were modest: 25.8% for
corticosteroid injection into the levator muscles compared to 9.1% for EGS at 12 months
follow-up. Botulinum toxin injection was recently tested in a small randomized controlled trial
and failed to show any benefit.23 Sacral nerve stimulation was reported to be beneficial in an
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uncontrolled study, but when assessed by intent to treat, only 12 of 27 patients reported benefit.
24
We investigated the mechanism by which biofeedback and other treatments improve the
symptoms of LAS by performing standard anorectal manometry and balloon defecation tests
at baseline and at 1 and 3 months follow-up. Our a priori hypothesis was that these treatments
would reduce resting anal canal pressures, improve the ability to relax the pelvic floor during
straining, and improve the ability to evacuate a water-filled balloon, all of which are indications
of decreased pelvic floor muscle tension. There was no significant improvement in anal canal
resting pressure except in the group treated with massage. However, we did see significant
improvement in the ability to relax pelvic floor muscles and to evacuate a balloon from the
rectum in all patients who reported adequate relief of pain regardless of the treatment to which
they were exposed. Treatment with biofeedback and EGS were also associated with increases
in rectal sensitivity as shown by significant reductions in the urge threshold and the maximum
tolerable volume of rectal distention in patients with a highly likely diagnosis. These changes
in rectal sensitivity may have been mediated by increases in smooth muscle tone since
compliance decreased at one month following biofeedback training. These findings suggest
that the mechanism for treatment improvement is the same for these three treatments, although
the treatments differ in how effective they are at relieving the symptoms of LAS.
The Rome II (and also the Rome III) diagnostic criteria make a distinction between patients
who report tenderness on palpation of the levator muscles versus those who do not by assigning
a “highly likely” diagnosis of LAS to the former group. One goal of this study was to evaluate
this distinction. At baseline, we found no differences between these groups of patients with
respect to pain intensity, number of days per month with pain, anal canal pressures, or rectal
sensitivity. However, patients who reported tenderness on digital palpation were less likely to
show relaxation of pelvic floor muscles when straining, and most were unable to evacuate a
water-filled balloon (simulated defecation). There was also a striking difference in the
responsiveness of these patients to all treatments considered: patients who reported tenderness
on palpation were significantly more likely to benefit from biofeedback, EGS, and massage.
Thus, the distinction based on whether patients report tenderness on digital palpation is an
important one, and clinicians may wish to consider this physical sign a requirement for the
diagnosis of LAS and for initiation of biofeedback treatment. Future research should address
whether there may be a different pathophysiological explanation, or possibly a psychological
basis, for rectal pain in patients with only a possible diagnosis of LAS.
These data show that the physiological mechanisms responsible for LAS and dyssynergic
defecation are similar. Eight-six percent of patients with a highly likely diagnosis of LAS failed
to relax pelvic floor muscles (i.e., to decrease anal canal pressures) when straining to defecate
and 87% were unable to evacuate a water-filled balloon. Although the patients with LAS in
this study did not have a low stool frequency suggestive of constipation, we found that patients
who improved with any of the three treatments investigated (1) demonstrated improved
relaxation of anal canal pressures during straining or improved ability to evacuate a water-
filled balloon, and (2) showed a significant increase in stool frequency. The fact that stool
frequency was within the normal range at baseline may be a consequence of our study entry
criteria, which required any patient meeting criteria for functional constipation to be excluded.
Moreover, a biofeedback protocol developed to treat dyssynergic defecation was the most
effective treatment for LAS and was associated with improved ability to relax pelvic floor
muscles when straining, and improved ability to evacuate a balloon. Thus, LAS and
dyssynergic defecation appear to represent different symptom manifestations of the same
underlying disorder.
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These observations also show that pelvic floor dyssynergia (i.e., inability to relax pelvic floor
muscles when straining to defecate) may present without symptoms of constipation or
obstructed defecation, whereas we had hitherto assumed that pelvic floor dyssynergia would
invariably lead to obstructed defecation. This suggest the hypothesis that other factors such as
whole gut transit and stool consistency interact with pelvic floor physiology to determine which
symptoms develop. Further research is needed to explore this hypothesis.
Study limitations
It was not possible to mask either patients or the therapist to treatment assignment. However,
by having all outcome assessments performed by a nurse who was unaware of treatment
assignment, we were able to exclude experimenter bias as an explanation for these findings.
A second limitation is that there was no placebo group, so we are unable to conclude that the
least effective treatment, digital massage, is better than placebo. However, we can conclude
that biofeedback is more effective than EGS, which is in turn more effective than massage. A
third limitation is that we did not include measures of quality of life to assess the impact of
LAS on this outcome, and whether treatment of LAS mitigates this impact.
Clinical application
This study demonstrates that biofeedback is an effective treatment which can be recommended
for the treatment of LAS. We have also identified criteria which can be used to select the
patients most likely to have a successful outcome, namely those with tenderness on palpation
of the levator ani muscles and inability to evacuate a 50-ml water filled balloon. Of equal value
to clinicians, our data show that digital massage, a treatment frequently recommended for LAS,
is ineffective and should be abandoned. EGS was significantly less effective than biofeedback
but may retain a role in the treatment of LAS when biofeedback therapy is not available.
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Flow chart showing the disposition of all subjects considered for the trial.
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Number of pain days for the previous month. Dark gray bars are Biofeedback-treated patients,
light gray bars are EGS-treated patients, and white bars are patients treated with digital massage
and sitz baths. Vertical lines show 95% confidence intervals. Patients with a highly likely
diagnosis of LAS are shown separately from patients with only a possible diagnosis.
*Significantly different from the Biofeedback group at p<0.025; #significantly different from
the EGS group at p<0.025.
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Average of weekly pain intensity rating for previous month. Pain was rated on a 10cm visual
analog scale for the worst rectal pain in the previous week. Dark gray bars are Biofeedback-
treated patients, light gray bars are EGS-treated patients, and white bars are patients treated
with digital massage and Sitz baths. Vertical lines show 95% confidence intervals. Patients
with a highly likely diagnosis of LAS are shown separately from patients with only a possible
diagnosis. *Significantly different from the Biofeedback group at p<0.025; #significantly
different from the EGS group at p<0.025.
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Percent reporting adequate relief at follow-up. Dark gray bars are Biofeedback-treated patients,
light gray bars are EGS-treated patients, and white bars are patients treated with digital massage
and sitz baths. Vertical lines show 95% confidence intervals. Patients with a highly likely
diagnosis of LAS are shown separately from patients with only a possible diagnosis.
*Significantly different from the Biofeedback group at p<0.025; #significantly different from
the EGS group at p<0.025.
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Subjective change in pain, rated -2 for “a lot worse”, -1 for “a little worse”, 0 for “same as
before”, +1 for “a little better”, +2 for “fairly better”, and +3 for “a lot better or cured”. Dark
gray bars are Biofeedback-treated patients, light gray bars are EGS-treated patients, and white
bars are patients treated with digital massage and sitz baths. Vertical lines show 95% confidence
intervals. Patients with a highly likely diagnosis of LAS are shown separately from patients
with only a possible diagnosis. *Significantly different from the Biofeedback group at
p<0.025; #significantly different from the EGS group at p<0.025.
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Table 2
































Patients with missing data for any reason were assumed to be non-responders and were retained in the analysis
E
Biofeedback superior to EGS, p<0.01.
M
Biofeedback superior to massage, p<0.01.
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